Viridian Therapeutics (NASDAQ:VRDN) Research Coverage Started at The Goldman Sachs Group

The Goldman Sachs Group initiated coverage on shares of Viridian Therapeutics (NASDAQ:VRDNFree Report) in a report released on Thursday morning, MarketBeat.com reports. The firm issued a buy rating and a $23.00 target price on the stock.

VRDN has been the topic of several other reports. LADENBURG THALM/SH SH downgraded shares of Viridian Therapeutics from a buy rating to a neutral rating in a research note on Thursday, May 9th. Wedbush lifted their target price on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an outperform rating in a research note on Wednesday, February 28th. B. Riley downgraded shares of Viridian Therapeutics from a buy rating to a neutral rating and decreased their target price for the stock from $25.00 to $20.00 in a research note on Thursday, May 9th. Needham & Company LLC reaffirmed a buy rating and issued a $30.00 target price on shares of Viridian Therapeutics in a research note on Thursday, May 9th. Finally, HC Wainwright reduced their price objective on shares of Viridian Therapeutics from $37.00 to $27.00 and set a buy rating on the stock in a research report on Thursday, May 9th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $33.55.

Read Our Latest Stock Analysis on VRDN

Viridian Therapeutics Trading Down 0.9 %

Shares of VRDN opened at $12.23 on Thursday. The firm has a market cap of $780.52 million, a price-to-earnings ratio of -2.72 and a beta of 1.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.99 and a current ratio of 23.99. Viridian Therapeutics has a fifty-two week low of $10.93 and a fifty-two week high of $28.35. The firm has a 50 day moving average price of $14.24 and a 200-day moving average price of $17.50.

Viridian Therapeutics (NASDAQ:VRDNGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.28. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative return on equity of 92.04%. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period in the previous year, the firm earned ($1.61) earnings per share. The firm’s revenue for the quarter was down 26.5% on a year-over-year basis. As a group, equities research analysts forecast that Viridian Therapeutics will post -3.61 earnings per share for the current year.

Institutional Trading of Viridian Therapeutics

A number of hedge funds have recently modified their holdings of VRDN. Ameritas Investment Partners Inc. boosted its holdings in shares of Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after buying an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Viridian Therapeutics by 122.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock valued at $182,000 after buying an additional 4,610 shares in the last quarter. Arizona State Retirement System bought a new stake in shares of Viridian Therapeutics during the 4th quarter valued at $208,000. Principal Financial Group Inc. boosted its holdings in shares of Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock valued at $209,000 after buying an additional 1,058 shares in the last quarter. Finally, Dark Forest Capital Management LP bought a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at $264,000.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

See Also

Analyst Recommendations for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.